■ Abstract Objective Nitric oxide (NO) inhibits thrombus formation, vascular contraction, and smooth muscle cell proliferation. We investigated whether NO release is enhanced after endothelial NO synthase (eNOS) gene transfer in atherosclerotic human carotid artery ex vivo. Methods and Results Western blotting and immunohistochemistry revealed that transduction enhanced eNOS expression; however, neither nitrite production nor NO release measured by porphyrinic microsensor was altered. In contrast, transduction enhanced NO production in non-atherosclerotic rat aorta and human internal mammary artery. In transduced carotid artery, calcium-dependent eNOS activity was minimal and did not differ from control conditions. Vascular tetrahydrobiopterin concentrations did not differ between the experimental groups. Treatment of transduced carotid artery with FAD, FMN, NADPH, L-arginine, and either sepiapterin or tetrahydrobiopterin did not alter NO release. Superoxide formation was similar in transduced carotid artery and control. Treatment of transduced carotid artery with superoxide dismutase (SOD), PEG-SOD, PEG-catalase did not affect NO release. Conclusions eNOS transduction in atherosclerotic human carotid artery results in high expression without any measurable activity of the recombinant protein. The defect in the atherosclerotic vessels is neither caused by cofactor deficiency nor enhanced NO breakdown. Since angioplasty is performed in atherosclerotic arteries, eNOS gene therapy is unlikely to provide clinical benefit.
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Introduction
Gene therapy is a promising therapeutic approach for restenotic lesions, and for in-stent-restenosis in particular [21, 32] . Nitric oxide (NO) inhibits platelet aggregation, induces vascular relaxation, and impairs vascular smooth muscle cell (VSMC) proliferation by specific actions on cell cycle progression [11, 12, 25] . Moreover, NO counterregulates the induction of adhesion molecule expression and leucocyte accumulation as well as other inflammatory alterations occurring in atherosclerotic arteries [3] . Therefore, overexpression of endothelial NO synthase (eNOS) seems a reasonable concept for the local treatment of restenotic lesions. This is particularly plausible as balloon dilatation is performed in atherosclerotic vessels which exhibit reduced eNOS expression [17] . NO formation is catalyzed by at least 3 different isoforms of NOS. Neuronal NOS is constitutively expressed in neurons and some other cell types; it generates low levels of NO. Expression of inducible NOS (iNOS) can be induced by cytokines in many different cell types; this isoform generates high levels of NO. Endothelial NOS is constitutively expressed in endothelial cells and some other cell types, and similar to nNOS, it releases low levels of NO. The major reason responsible for the different enzyme kinetics is the calcium-dependency of nNOS and eNOS [9] .
Normal function of eNOS is critically dependent on the availability of the substrate L-arginine and several cofactors as well. Indeed, L-arginine administration increases endothelial NO synthesis in hypercholesterolemia [7] , and tetrahydrobiopterin (BH 4 ) infusion restores endothelium-dependent relaxation in hypercholesterolemic humans [22] . In addition, reduced NO activity may not only be caused by diminished synthesis, but also by enhanced catabolism of the radical, as the half-life of NO is determined by its reaction with oxyhemoglobin and superoxide (O 2 -) [31] . Thus, atherosclerotic arteries may have a diminished NO production because of both reduced cofactor concentration and enhanced O 2 -production [18] . As treatment of restenosis by gene delivery would have to be performed in such diseased vessels, we examined whether eNOS transduction into atherosclerotic human carotid arteries (CA) ex vivo is indeed followed by an enhanced NO production.
Methods
■ Recombinant adenovirus
An adenoviral vector for expression of human placental alkaline phosphatase (AdhPAP) was prepared as described [19] . The vector for expression of eNOS (AdeNOS) was provided by Dr Stefan Janssens, Leuven, Belgium [1] . The titer of purified viruses was determined by plaque assay on 293 cells as described [14] .Viral titers ranged from 2ϫ10 10 to 2ϫ10 11 pfu/ml for all preparations. The titer of wild type virus was determined by plaque assay on A549 cells using the same conditions and was below 1 in 10 9 pfu/ml. ■ Cell culture, tissue culture, transduction 293 cells and A549 cells were obtained from ATCC and cultured as recommended. CA tissue specimens were obtained from 50 human donors undergoing endarterectomy. The study was reviewed by the ethics committee of the University Hospital, and the patients gave their informed consent prior to inclusion in the study. Mean age was 71±8; males: 72%; smokers: 52%; hypercholesterolemia; 56%; hypertension: 70%; diabetes: 34%. 86% of patients were treated with aspirin, 64% with a statin. No difference between eNOS expression, risk factors, and specific medication was observed in the CA specimens. All specimens exhibited macroscopic evidence of atherosclerotic changes (fatty streaks, advanced lesions, atheromas). The time window between excision of CA and beginning of gene transfer was between 3 and 6 hours for all the experiments. Specimens were cut into small pieces (5ϫ5 mm) under sterile conditions, while tissue pieces with large necrotic areas were avoided as the material was too friable. Internal mammary artery tissue segments were obtained from patients undergoing coronary artery bypass grafting. Atherosclerotic changes were excluded by a stereo microscope (Leitz, Heerbrugg, Switzerland) at 30ϫ magnification. Rat aorta served as additional control for some experiments. Tissue pieces were incubated with a viral titer of 1ϫ10 9 pfu/ml for 2 hours at 37°and then kept in DMEM with 10% FCS for an additional 48 hours [20] . Tissue from CA, internal mammary artery and rat aorta was treated in an identical manner. Transduction was confirmed by staining of AdhPAP transfected specimens with NBT/BCIP (GIBCO) as described [23] , and tissue specimens were analyzed by a stereo microscope (Leitz, Heerbrugg, Switzerland) at 30ϫ magnification.
■ Western blot analysis
Western blot analysis was performed on tissue specimens as described [24] . 60 μg protein were loaded per lane, resolved by SDS-PAGE under reducing conditions, blotted onto PVDF membranes and analyzed by chemiluminescence (Amersham). Equal loading of proteins was controlled for by staining with Ponceau S as well as by blotting for α-tubulin.
■ Immunohistochemistry
Tissue specimens were prepared as described [13] . Specimens were incubated with anti-eNOS monoclonal antibody (N30020; Transduction Laboratories, Lexington, USA) at 4°overnight. Immunostaining was performed with an FITC-conjugated goat anti-mouse antibody (F479; Dako, Glostrup, Denmark) at 1:10 dilution followed by counterstaining with Evans blue 0.1% (Merck, Darmstadt, Germany) and mounting in glycergel medium (Dako) [13] . Negative controls were obtained by replacing the primary antibody with an irrelevant anti CD18 antibody (1110; Monosan, Uden, Netherlands) as well as with antibodies for iNOS and nNOS (N32020 and N31020, respectively; Transduction Laboratories); positive controls were generated on human tonsil for eNOS, porcine pituitary gland for nNOS, and human macrophage cultures for iNOS [13] .
■ Nitrite release
After transduction, tissue pieces were kept in DMEM with 20% FCS at 37°for 48 hours. This procedure has been shown to activate eNOS both in VSMC [25] and in vascular tissue [26] . Tissue pieces were homogenized and subsequently diluted in water. Quantitation of nitrite was performed as described [2] .
■ NO release
After transduction, tissue pieces were treated as described for nitrite measurement. NO release was stimulated by 10 -5 M calcium ionophore A23187, and NO was measured by a porphyrinic microsensor as described [28] .
■ eNOS activity
Vessels were homogenized in 600 μl of a solution containing 50 mM Tris pH 7.4, 250 mM sucrose, and 2 mM EDTA. 50 μl of homogenate was incubated at room temperature in 200 μl incubation medium with or without 2 mM L-NAME, containing 1 mM nicotine adenine dinucleotide phosphate (NADPH), 4 mM CaCl 2 , 1 mM DTT, 15 μM tetrahydrobiopterin, 10 μM flavin adenine dinucleotide (FAD), 10 μM flavin mononucleotide (FMN), 10 μg/ml calmodulin, 0.2 μCi 3H-arginine, and 50 μM unlabeled L-arginine. The reaction was stopped after 1 h by addition of HEPES (100 mM), EDTA (4 mM), EGTA (2 mM) pH 5.5 containing unlabeled amino acid markers. For some experiments, calcium was omitted in the buffer. Radiolabeled arginine was separated from citrulline on silica gel thin-layer chromatography plates using chloroform:methanol:NH 4 OH:water 1:4:2:1 vol/vol as solvent and developed with fluoraldehyde-ophthaladehyde reagent.The relevant bands were scraped from the plate and counted in a scintillation counter. Citrulline production was expressed as dpm citrulline/h/g wet weight.
■ Superoxide release
After transduction, tissue pieces were kept in DMEM with 20% FCS at 37°for 48 hours. O 2 -production was measured by coelenterazine chemoluminescence as described using a Turner Design Model TD-20/20 luminometer (Turner Designs, Sunnyvale, CA) [27] . O 2 -re-lease rate was expressed as relative light units/minute/ mg dry weight. Absolute values of O 2 -release were determined with known quantities of xanthine and xanthine oxidase by the SOD inhibitable cytochrome c reduction using the molar extinction coefficient for cytochrome c (21mmol/l -1 · cm -1 ) and expressed as nmol/minute/mg dry weight [18] .
■ BH 4 concentrations
BH 4 was measured in non-transduced, control vector treated, and eNOS vector treated carotid artery as described [10] .
■ Statistics
Results represent the mean value of 5 to 8 experiments as indicated in the text. Data are expressed as mean ± standard error of the mean (S.E.M.) and statistical comparisons were performed using analysis of variance (ANOVA).A two-tailed p value of less than 0.05 was considered to indicate a significant difference.
Results
■ Expression of eNOS
Adenoviral transduction of human CA was assessed by human placental alkaline phosphatase (hPAP). NBT/BCIP staining revealed the presence of functional hPAP in CA transduced with hPAP adenovirus (hPAP), but not with control adenovirus (ΔE1) nor under nontransduced conditions indicating good transduction using this vector (Fig. 1A) . eNOS expression in human CA after adenoviral transduction was first examined by Western blot analysis, which demonstrated a high expression after transduction with the eNOS adenovirus (eNOS), while the protein was barely detectable in the control adenovirus group (ΔE1) nor under non-trans- duced conditions (Fig. 1B) . Immunohistochemical analysis of eNOS expression revealed a strong signal in endothelial and to a lesser degree in subendothelial cells of transduced specimens. Consistent with the Western blots, no significant staining was detected in control adenovirus transduced tissues or in non-transduced samples (Fig. 1C) . This pattern of eNOS expression in atherosclerotic carotid artery was observed in most transduced specimens; however, in 2 out of 10 samples, eNOS expression was not clearly increased as compared to control specimens, which is consistent with the heterogenic morphology of the atherosclerotic tissue. Expression of iNOS and nNOS was examined in serial sections; no staining was observed in non-transduced and transduced specimens (data not shown).
Western blotting revealed that eNOS expression was 8.75-fold higher in non-atherosclerotic human internal mammary artery (MA) as compared side by side to atherosclerotic carotid artery (p<0.05; n=4-5; Fig. 2 , left panel). Indeed, only prolonged exposure times permitted to detect a signal for eNOS in the carotid artery samples.After adenoviral transduction, eNOS expression increased by 10.7-fold in MA (p<0.01 for control vs. eNOS and for ΔE1 vs. eNOS; n=5; Fig. 3, left panel) and by 9.9-fold in CA (p<0.05 for control vs. eNOS and for ΔE1 vs. eNOS; n=5; Fig. 3, right panel) . Moreover, eNOS expression was similar in MA and CA transduced with eNOS (p=0.55.; n=5).
■ Release of NO
NO release from CA after eNOS gene transfer was first assessed by measuring nitrite (NO 2 -) tissue levels. 48 hours after transduction, the cumulative nitrite level was 0.378±0.249 μmol/g for non-transduced conditions, 0.854±0.495 μmol/g for control adenovirus (ΔE1), and 1.110±0.696 μmol/g for eNOS adenovirus (eNOS) (p=0.76 for control vs. eNOS; p=0.46 for control vs. ΔE1; p=0.70 for AdΔE1 vs. AdeNOS; n=8; Fig. 4, right panel) . To compare NO release from CA with that from an arterial tissue without atherosclerotic changes, a parallel set of experiments was performed in rat aorta. In contrast to CA, eNOS gene transfer enhanced NO release from this tissue. Indeed, 48 hours after transduction, the nitrite tissue level was 0.914±0.562 μmol/g for non-trans- Fig. 2 Endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) release in human arteries. eNOS expression (left panel) is determined by Western blots and indicated in arbitrary densitometric units; expression is higher in internal mammary artery (MA) as compared to atherosclerotic carotid artery (CA). NO release (right panel) is measured by a porphyrinic microsensor and it is higher in MA than CA Fig. 3 Endothelial nitric oxide synthase (eNOS) expression in transduced human arteries. Expression is determined by Western blots and indicated in arbitrary densitometric units. The eNOS signal is related to that of α-tubulin (αT) as loading control. eNOS expression is high in internal mammary artery (MA) and atherosclerotic carotid artery (CA) transduced with eNOS adenovirus (eNOS), while a weak signal is detected in both vessels with control adenovirus (ΔE1) or under non-transduced conditions duced conditions, 6.590±1.362 μmol/g for control adenovirus (ΔE1), and 11.112±1.493 μmol/g for eNOS adenovirus (eNOS) (p=0.0001 for control vs. eNOS; p<0.01 for control vs. ΔE1; p<0.05 for ΔE1 vs. eNOS; n=5; Fig. 4 , left panel). An effect of control adenovirus on NO release after eNOS transduction has been observed in non-atherosclerotic tissue in previous studies as well [25, 26] . To confirm that eNOS gene transfer did not affect NO production in CA, the release of NO was also measured by a porphyrinic microsensor upon stimulation with 10 -5 M calcium ionophore A23187.All the measurements were performed within 10 seconds. NO release was similar under non-transduced conditions and in tissue treated with control adenovirus (ΔE1) or with eNOS adenovirus (eNOS) (p=0.82 for control vs. ΔE1; p=0.45 for control vs. eNOS; p=0.92 for ΔE1 vs. eNOS; n=8; Fig. 4, upper insert) .
To study NO production in a non-atherosclerotic human tissue as well, NO release from transduced MA was examined. As compared to control conditions (100%; 85±27 nM), NO production of this tissue was 89±22% (80±40 nM) for control adenovirus (ΔE1) and 254±40% (228±106 nM) for eNOS adenovirus (eNOS) (p<0.005 for control vs. eNOS; p<0.005 for ΔE1 vs. eNOS; p=0.95 for control vs. ΔE1; n=4; Fig. 5A ). MA NO production under non-transduced conditions was 85±27 nM and hence much higher as compared to CA (5±3 nM; n=9; p=0.001; Fig. 2, right panel) . Again, NO production in CA was not affected by transduction of eNOS, while that in MA increased (Fig. 5B) .
To assess whether the atherosclerotic tissue deteriorated during the 48 h incubation period, NO release was compared in freshly isolated versus incubated CA and found to be identical (fresh: 8.0±4.6 nM; incubated: 7.5±2.6 nM; n=4; p=0.93). Consistent with a minimal NO production, eNOS activity was barely detectable in CA; indeed, the values were several thousand fold lower as compared to non atherosclerotic arterial tissue from various species including humans [8, 10] . In the absence of calcium, no enzyme activity was detected, indicating that iNOS does not contribute to this activity. Enzyme activity was not affected by transduction (p=n.s. for non-transduced vs. eNOS; p=n.s. for non-transduced vs. ΔE1; p=n.s. for ΔE1 vs. eNOS; n=5; Table) . To address whether cofactor deficiency in the atherosclerotic tissue was responsible for the lack of enhanced NO production after transduction, tissue concentrations of BH 4 were determined. BH 4 concentrations were similar for nontransduced (3.17±1.18 pmol/mg), ΔE1-transduced (6.20±2.27 pmol/mg), and eNOS-transduced tissue (7.63±4.72 pmol/mg; n=3; p=n.s.). Moreover, tissue specimens were incubated with BH 4 (10 -4 M), FAD (5ϫ10 -6 M), FMN (5ϫ10 -6 M), NADPH (5ϫ10 -4 M), and L-arginine (10 -4 M) for 3 hours before NO was measured. NO release was not altered in all three experimental groups (non-transduced, ΔE1, eNOS) as compared to conditions without cofactor addition (n=4; p values ranging from 0.59 to 0.99; Table) . Similar results were obtained when these cofactors were present during the 48 h period between transfection and measurement of NO release (all values <15 nM NO; n=4; p values ranging from 0.67 to 0.93; data not shown). Further, no change in NO release was observed when sepiapterin instead of BH 4 was used (all values <15 nM NO; n=2; data not shown).
■ Release of O 2 -
To analyze whether increased O 2 -generation in transduced CA could lead to enhanced catabolism of NO, the release of O 2 -was measured by coelenterazine chemoluminescence. O 2 -production was 0.245 nmol/min/mg dry weight for non-transduced conditions, 0.335 nmol/min/mg dry weight for control adenovirus (ΔE1), and 0.254 nmol/min/mg dry weight for eNOS aden- Fig. 4 Nitric oxide (NO) and superoxide (O 2 -) production in transduced atherosclerotic human carotid artery (CA). Nitrite production is similar in CA transduced with eNOS adenovirus (eNOS) as compared to control adenovirus (ΔE1) and non-transduced conditions. In contrast, nitrite production is significantly higher in rat aorta transduced with eNOS as compared to ΔE1 and non-transduced conditions. Nitric oxide (NO) production is shown in the upper insert and is similar in CA transduced with eNOS as compared to ΔE1 and non-transduced conditions. Superoxide (O 2 -) production is shown in the lower insert and is also similar in CA transduced with eNOS as compared to ΔE1 and non-transduced conditions ovirus (eNOS) (p=0.97 for non-transduced vs. eNOS; p=0.59 for non-transduced vs. ΔE1; p=0.71 for ΔE1 vs. eNOS; n=5; Fig. 4 lower insert) . To address whether superoxide generated in the atherosclerotic tissue reacted with NO, the porphyrinic microsensor measurement was repeated in the presence of superoxide dismutase (SOD; 25 U/ml) or polyethylene glycol superoxide dismutase (PEG-SOD; 300 U/ml). NO release was not altered in all three experimental groups (non-transduced, ΔE1, eNOS) as compared to conditions without addition of SOD or PEG-SOD (p values ranging from 0.45 to 0.99; n=5; Table) . To assess whether H 2 O 2 was involved in NO breakdown, the microsensor measurement was repeated in the presence of PEG-catalase (1000 U/ml). NO release was not altered in all three experimental groups (nontransduced, ΔE1, eNOS) as compared to conditions without addition of PEG-catalase (p values ranging from 0.43 to 0.95; n=4; Table) . As a positive control for the action of PEG-SOD and PEG-catalase preparations, the effect of 300 U/ml of PEG-SOD and 1000 U/ml of PEGcatalase on conversion of dichlorodihydrofluorescein diacetate to dichlorodihydrofluorescein was determined. PEG-SOD reduced the conversion induced by 1 mM SIN-1 to 26±0.5% of control (p<0.001; n=6). PEGcatalase also inhibited conversion induced by 1 mM H 2 O 2 (54±0.6% of control; p<0.0001; n=6).
Discussion
This study demonstrates that adenoviral transduction of atherosclerotic human CA results in marked eNOS expression without enhancing NO release, indicating that the recombinant enzyme is dysfunctional in ather- osclerotic human vessels. Expression of the transduced genes in CA was observed in both endothelium and subendothelial cells. After eNOS transduction, VSMC and adventitial fibrocytes can release NO [8, 25] ; thus, medial and adventitial cells may contribute to NO release in transduced vessels. Therefore, endothelial damage or even denudation during PTCA is not a reason to refrain from eNOS gene transfer. However, the lack of NO release indicates that eNOS gene transfer is not a reasonable gene therapy strategy for restenosis or atherosclerotic vascular disease.
A higher eNOS expression in transduced atherosclerotic CA as compared to control tissue was observed in 8 out of 10 samples. In the other two samples, no clear increase in eNOS expression was present as compared to control. Hence, transfection of atherosclerotic CA is somewhat variable, presumably due to its morphological heterogeneity. Nevertheless, most of the samples exhibited a higher eNOS expression as compared to control. Therefore, the missing increase in NO release in all the transduced samples can not be explained by variability of transfection. NO production after eNOS transduction was determined by both nitrite formation and NO release. Neither method detected an enhanced NO production in transduced CA as compared to control tissue. Rat aorta and human internal mammary artery served as non-atherosclerotic controls for NO formation after eNOS transduction. These controls were chosen because of the obvious difficulties to obtain non-atherosclerotic human CA. Experiments were performed in parallel with those in CA and revealed both an enhanced eNOS expression and NO production after eNOS transduction, demonstrating that overexpression of eNOS enhances NO release only in non-atherosclerotic tissue; therefore, similar to endogenous eNOS, the transduced enzyme seems to be dysfunctional in atherosclerotic tissue. The lack of NO release is not only consistent with dysfunction of eNOS, but also with absence of iNOS expression in the CA tissue; as the specimens originated from long-standing lesions with presumably stable plaques, inflammation probably does not play a major role in these lesions any longer.
In the rat aorta, the control adenovirus had some effect on nitrite formation, suggesting that the vector induces the endogenous enzyme. Consistent with this interpretation, there was a very faint staining for eNOS in the ΔE1 transduced CA. As nitrite formation in the latter was neither altered by ΔE1 nor eNOS adenovirus, atherosclerosis may induce a similar functional defect of both the endogenous and the recombinant enzyme. However, the control vector did not have any effect on NO formation as determined by the porphyrinic microsensor in the human internal mammary artery. This observation offers the alternative explanation that the effect of ΔE1 on nitrite formation does not depend on NO or, with lower probability, that it is influenced by the type of species or vessel involved.
Activity of eNOS in CA was determined by a highly sensitive modification of the citrulline assay and was almost undetectable both under control conditions and after eNOS transduction. Indeed, the values were several thousand fold lower as compared to non-atherosclerotic arterial tissue from various species including humans [5, 16] . This observation demonstrates that eNOS activity is not enhanced after transduction and is consistent with the minimal NO release from the atherosclerotic tissue. For catalysis of NO formation from L-arginine, eNOS requires several cofactors. Indeed, FAD and FMN are necessary for electron transport from NADPH to oxygen, while BH 4 is required for efficient generation of NO from reduced oxygen and L-arginine. Deficiency of these cofactors may hamper the function of the endogenous as well as the recombinant enzyme. In fact, atherosclerotic vessels contain lower cofactor concentrations and release less NO as compared to normal vessels, and cofactor infusion can improve NO formation [7, 22, 31] . Hence, BH 4 concentrations in CA after eNOS transduction were determined. Concentrations of the cofactor did not differ in transduced as compared to control tissue. Further, NO release from CA after eNOS transduction was examined in the presence of cofactor supplementation. Under these conditions, however, NO release did not differ in transduced as compared to control tissue. Although some degradation of cofactors in culture can not be excluded, these data suggest that cofactor deficiency alone can not account for the dysfunction of the recombinant enzyme. Hence, the lack of eNOS activity in transduced atherosclerotic tissue must be related to other mechanisms as well. Indeed, it is conceivable that the presence of oxidized LDL in the atherosclerotic tissue may impair signal transduction activation of eNOS; furthermore, competitive inhibitors of eNOS such as ADMA may be synthesized in the endothelium causing decreased eNOS activity [4] . In case of suboptimal BH 4 concentrations, uncoupling of eNOS occurs, and the enzyme itself becomes a source of O 2 -. Hence, the lack of an increase in NO production after eNOS transduction may be related to increased O 2 -formation resulting in NO catabolism. Therefore, O 2 -generation in CA was determined. O 2 -release did not differ in eNOS transduced tissue as compared to control conditions, indicating that enhanced NO catabolism is not a probable reason for the unaltered NO release after transduction, and supporting the interpretation that cofactor deficiency can not be the sole reason for the dysfunction of recombinant eNOS. Consistent with these observations, NO production remained identical in the presence of SOD and PEG-SOD. Similarly, PEG-catalase did not affect the formation of NO, indicating that NO catabolism by H 2 O 2 can be excluded as a reason for the unaltered NO release after transduction as well.
In theory, eNOS gene transfer is a very reasonable therapeutic strategy for vascular disease, as NO does not only inhibit VSMC proliferation,but also impairs thrombus formation eliminating a major source of mitogens for VSMC, and interferes with adhesion molecule expression as well as leucocyte invasion [3, 12] . In addition, expression of eNOS is reduced in atherosclerotic tissue, demanding substitution by a recombinant enzyme [17] . For the treatment of restenosis, however, eNOS gene transfer is unlikely to provide clinical benefit; such vessels are severely atherosclerotic, and, according to our data, transduction would result in expression of an inactive enzyme. Since eNOS gene transfer has been described to reduce vascular smooth muscle cell proliferation [6] and restenosis in a pig and a mouse model [15, 29, 30] , the inactivity of recombinant eNOS in the human CA is surprising; however, differences in gender, in the degree of atherosclerosis, and/or in the pathogenesis of atherosclerosis may well account for the different activity of recombinant eNOS in these models and the human tissue. Thus, transduction of a gene can result in unexpected features in the respective human tissue, indicating that ex vivo studies with the relevant tissue should be performed before starting clinical trials. In contrast to restenosis, coronary artery bypass graft disease still represents a promising target for eNOS gene transfer. Indeed, the saphenous vein is not atherosclerotic when implanted as bypass graft. Moreover, eNOS transduction inhibits biological features of bypass graft disease in the human saphenous vein ex vivo [26] . Therefore, in its current state, successful application of gene transfer technology for treating vascular diseases requires a specifically tailored strategy, which does not only take into account efficieny of transduction and duration of expression, but also the biological characteristics of the respective human tissue.
